Quadrature Capital LTD Erasca, Inc. Call Options Transaction History
Quadrature Capital LTD
- $4.51 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$27.5 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$21.1 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$19.8 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$15.9 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$15.5 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $149M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...